14:25 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Several analysts raised their price targets a day after the company reported a 28% quarterly sales increase, helped by a strong performance for the new diabetes drug Mounjaro. Lilly also completed its purchase of DICE Therapeutics, expanding its immunology portfolio. Lilly was up 2%, to $530.09, on Wednesday after rising 15% Tuesday. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

August 09, 2023 14:40 ET (18:40 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Out 2023 até Nov 2023 Click aqui para mais gráficos Eli Lilly.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Nov 2022 até Nov 2023 Click aqui para mais gráficos Eli Lilly.